样式: 排序: IF: - GO 导出 标记为已读
-
Issue Information Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-04-26
No abstract is available for this article.
-
Impact of COVID‐19 Nonpharmaceutical Interventions on Respiratory Syncytial Virus Infections in Hospitalized Children Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-04-24 Yingfeng Lu, Qinghui Chen, Shaolong Ren, Youyi Zhang, Liping Yi, Chen Qian, Jiaming Shen, Xiaofei Liu, Miao Jiang, Biying Wang, Jian Song, Xuejun Shao, Tao Zhang, Jianmei Tian, Genming Zhao
BackgroundNonpharmaceutical interventions (NPIs) targeted at SARS‐CoV‐2 have remarkably affected the circulation of other respiratory pathogens, including respiratory syncytial virus (RSV). This study aimed to assess the changes in epidemiological and clinical characteristics of RSV infections in hospitalized children before and during the pandemic in Suzhou, China.MethodsWe prospectively enrolled
-
Relative Effectiveness of the MF59®‐Adjuvanted Influenza Vaccine Versus High‐Dose and Non‐Adjuvanted Influenza Vaccines in Preventing Cardiorespiratory Hospitalizations During the 2019–2020 US Influenza Season Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-04-22 Mahrukh Imran, Joan Puig‐Barbera, Justin R. Ortiz, Lorena Lopez‐Gonzalez, Alex Dean, Machaon Bonafede, Mendel D. M. Haag
BackgroundAdults ≥ 65 years of age have suboptimal influenza vaccination responses compared to younger adults due to age‐related immunosenescence. Two vaccines were specifically developed to enhance protection: MF59‐adjuvanted trivalent influenza vaccine (aIIV3) and high‐dose egg‐based trivalent influenza vaccine (HD‐IIV3e).MethodsIn a retrospective cohort study conducted using US electronic medical
-
RSV Disease Burden in Primary Care in Italy: A Multi-Region Pediatric Study, Winter Season 2022–2023 Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-04-15 Michela Scarpaci, Sara Bracaloni, Enrica Esposito, Luigi De Angelis, Francesco Baglivo, Beatrice Casini, Donatella Panatto, Matilde Ogliastro, Daniela Loconsole, Maria Chironna, Elena Pariani, Laura Pellegrinelli, Elisabetta Pandolfi, Ileana Croci, Caterina Rizzo
Human respiratory syncytial virus (RSV) is one of the most frequent causes of respiratory infections in children under 5 years of age, but its socioeconomic impact and burden in primary care settings is still little studied.
-
Estimates of Seasonal Influenza Burden That Could Be Averted by Improved Influenza Vaccines in the Australian Population Aged Under 65 Years, 2015–2019 Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-04-19 Alicia N. Stein, Catherine G. A. Pendrey, David J. Muscatello, Paul G. Van Buynder, James E. Fielding, Jason C. Menche, Sheena G. Sullivan
BackgroundThe interpretation of relative vaccine effectiveness (rVE) of improved influenza vaccines is complex. Estimation of burden averted is useful to contextualise their potential impact across different seasons. For the population aged under 65 years in Australia, this study estimated the additional morbidity and mortality that could be averted using improved influenza vaccines.MethodsWe used
-
Evidence of Reverse Zoonotic Transmission of Human Seasonal Influenza A Virus (H1N1, H3N2) Among Cats Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-04-19 Sajid Umar, Semin Kim, Di Gao, Pu Chen
Human–animal interactions are closely intertwined. The connection between animal, human, and environmental health is becoming increasingly complicated with globalization, industrialization, and climate change. Since the beginning of the 20th century, the number of domestic cats has increased rapidly worldwide, including in China. There are approximately 600 million domesticated cats worldwide, including
-
Evaluating Pilot Implementation of ‘PenCS Flu Topbar’ App in Medical Practices to Improve National Immunisation Program–Funded Seasonal Influenza Vaccination in Central Queensland, Australia Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-04-16 Gulam Khandaker, Gwenda Chapman, Arifuzzaman Khan, Mahmudul Hassan Al Imam, Robert Menzies, Nicolas Smoll, Jacina Walker, Michael Kirk, Kerrie Wiley
BackgroundThe ‘PenCS Flu Topbar’ app was deployed in Central Queensland (CQ), Australia, medical practices through a pilot programme in March 2021.MethodsWe evaluated the app's user experience and examined whether the introduction of ‘PenCS Flu Topbar’ in medical practices could improve the coverage of NIP‐funded influenza vaccinations. We conducted a mixed‐method study including a qualitative analysis
-
Coronaviruses Among Swine Workers in Northern Vietnam Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-04-16 Laura A. Pulscher, Duy Tung Dao, Samantha G. Cody, Victor DelPrincipe, Gregory C. Gray
Dear Editor, The SARS-CoV-2 pandemic has highlighted the significant clinical relevance of coronaviruses, and the emergence of these pathogens has been associated with zoonotic transmission from animal reservoirs [1]. This has prompted enhanced surveillance for novel viral isolates especially in critical spillover settings, particularly at the human–animal interface. Coronaviruses circulate in many
-
Predictors of Respiratory Syncytial Virus, Influenza Virus, and Human Metapneumovirus Carriage in Children Under 5 Years With WHO‐Defined Fast‐Breathing Pneumonia in Pakistan Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-04-15 Muhammad Imran Nisar, Salima Kerai, Shahira Shahid, Muhammad Farrukh Qazi, Sarah Rehman, Fatima Aziz, Fyezah Jehan
BackgroundPneumonia is a leading cause of morbidity and mortality in children < 5 years. We describe nasopharyngeal carriage of respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and influenza virus among children with fast‐breathing pneumonia in Karachi, Pakistan.MethodsWe performed a cross‐sectional analysis of nasopharyngeal swabs from children aged 2–59 months with fast‐breathing
-
Immunogenicity of Enhanced Influenza Vaccines Against Mismatched Influenza Strains in Older Adults: A Review of Randomized Controlled Trials Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-04-10 John Youhanna, Vy Tran, Randall Hyer, Alexander Domnich
Antigenic drift is a major driver of viral evolution and a primary reason why influenza vaccines must be reformulated annually. Mismatch between vaccine and circulating viral strains negatively affects vaccine effectiveness and often contributes to higher rates of influenza‐related hospitalizations and deaths, particularly in years dominated by A(H3N2). Several countries recommend enhanced influenza
-
Breaking the Chain: Strategies to Stem Adenovirus Spread in Pakistan Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-04-08 Rayyan Vaid, Afra Sohail, Raam Kumar, Areeba Fareed
Adenovirus, a common respiratory pathogen, has witnessed a notable rise in incidence rates across various regions in Pakistan. Utilizing epidemiological data and climate records, this research discerns a potential linkage between the burgeoning adenovirus cases and alterations in regional climate patterns. Through statistical analysis and modeling techniques, the study aims to elucidate the relationship
-
High-Dose Quadrivalent Influenza Vaccine for Prevention of Cardiovascular and Respiratory Hospitalizations in Older Adults Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-04-03 Arto A. Palmu, Stephanie Pepin, Ritva K. Syrjänen, Karine Mari, Tamala Mallett Moore, Jukka Jokinen, Heta Nieminen, Terhi Kilpi, Sandrine I. Samson, Iris De Bruijn
We assessed the relative vaccine effectiveness (rVE) of high-dose quadrivalent influenza vaccine (QIV-HD) versus standard-dose quadrivalent influenza vaccine (QIV-SD) in preventing respiratory or cardiovascular hospitalizations in older adults.
-
Long-Distance Avian Migrants Fail to Bring 2.3.4.4b HPAI H5N1 Into Australia for a Second Year in a Row Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-03-31 Michelle Wille, Robyn Atkinson, Ian G. Barr, Charlotte Burgoyne, Alexander L. Bond, David Boyle, Maureen Christie, Meagan Dewar, Tegan Douglas, Teagan Fitzwater, Chris Hassell, Roz Jessop, Hiske Klaassen, Jennifer L. Lavers, Katherine K.-S. Leung, Jeremy Ringma, Duncan R. Sutherland, Marcel Klaassen
The current high-pathogenicity avian influenza (HPAI) H5N1 lineage 2.3.4.4b panzootic is having a profound impact on the poultry industry and wildlife [1, 2]. HPAI H5N1 emerged in poultry in 1996 and has caused outbreaks in wild bird populations episodically since 2005 [3], with the epidemiology of the virus changing substantially with the emergence of new lineages. A novel lineage emerged in 2014
-
Coinfection of Influenza A and B and Human OC43 Coronavirus in Normal Human Bronchial Epithelial Cells Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-04-01 JungHyun Kim, Brady T. Hickerson, Natalia A. Ilyushina
BackgroundInfluenza viruses and seasonal coronaviruses are pathogens transmitted via an airborne route that can cause respiratory diseases in humans that have similar symptoms such as fever, cough, and pneumonia. These two viruses can infect similar human tissues, such as the respiratory tract and nasal, bronchial, and alveolar epithelial cells. Influenza virus and seasonal coronavirus coinfections
-
Estimating Asymptomatic and Symptomatic Transmission of the COVID‐19 First Few Cases in Selenge Province, Mongolia Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-03-28 Davaalkham Dambadarjaa, Tsogt Mend, Andrew Shapiro, Mark S. Handcock, Undram Mandakh, Temuulen Enebish, Linh‐Vi Le, DJ Darwin R. Bandoy, Ambaselmaa Amarjargal, Bilegt Altangerel, Tuvshintur Chuluunbaatar, Uugantsetseg Guruuchin, Oyuntulkhuur Lkhagvajav, Oyunsuren Enebish
BackgroundFollowing the first locally transmitted case in Sukhbaatar soum, Selenge Province, we aimed to investigate the ultimate scale of the epidemic in the scenario of uninterrupted transmission.MethodsThis was a prospective case study following the locally modified WHO FFX cases generic protocol. A rapid response team collected data from November 14 to 29, 2020. We created a stochastic process
-
Issue Information Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-03-27
No abstract is available for this article.
-
Seroprevalence of SARS‐CoV‐2 in 10 Regional Capitals of Cameroon, October–December 2020 Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-03-27 Karampreet Sachathep, Yen T. Duong, Giles Reid, Emily Kainne Dokubo, Judith D. Shang, Clement B. Ndongmo, Ekali Gabriel, G. Tharp, Laura Eno Dimite, Adama N'Dir, Gordon Okpu, Francis M. Ogollah, Dubliss Nguafack, Martin C. Ntse, Gili Hrusa, Katherine Yuengling, Megan Tebbenhoff, Essomba René, Ngo Sack Françoise, Naah Tabala Felicity, Marie Claire Okomo, Anne‐Cecile Zoung‐Kanyi Bissek, Tiffany G. Harris
BackgroundCameroon was among the most affected African countries during the first wave of the COVID‐19 pandemic; however, the true prevalence of SARS‐CoV‐2 remains unknown.MethodsFrom October to December 2020, we conducted a cross‐sectional, age‐stratified SARS‐CoV‐2 seroepidemiological survey at 30 purposively selected community‐based sites across Cameroon's 10 regional capitals, sampling 10,000 individuals
-
Changes in Viral Dynamics Following the Legal Relaxation of COVID‐19 Mitigation Measures in Japan From Children to Adults: A Single Center Study, 2020–2023 Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-03-21 Yosuke Hirotsu, Yuki Nagakubo, Makoto Maejima, Masahiro Shibusawa, Kazuhiro Hosaka, Hitomi Sueki, Hitoshi Mochizuki, Masao Omata
IntroductionRespiratory infections are an ongoing global health challenge. The COVID‐19 pandemic triggered global nonpharmacological measures that reshaped public health. In Japan, the shift from legal to individual discretion in pandemic management started on May 8, 2023. However, it still unknown how the relaxation of measures affects respiratory pathogens across age groups.MethodsWe collected 16
-
Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-03-21 Caryn Myn Li Lim, Thamil Vaani Komarasamy, Nur Amelia Azreen Binti Adnan, Ammu Kutty Radhakrishnan, Vinod R. M. T. Balasubramaniam
Every year, influenza virus infections cause significant morbidity and mortality worldwide. They pose a substantial burden of disease, in terms of not only health but also the economy. Owing to the ability of influenza viruses to continuously evolve, annual seasonal influenza vaccines are necessary as a prophylaxis. However, current influenza vaccines against seasonal strains have limited effectiveness
-
Association of Monocyte Count With Lung Function and Exercise Capacity Among Hospitalized COVID‐19 Survivors: A 2‐Year Cohort Study Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-03-20 Xiaoying Gu, Lixue Huang, Xia Li, Yuting Zhou, Hui Zhang, Yeming Wang, Dan Cui, Ting Yu, Yimin Wang, Bin Cao
BackgroundAbnormal changes of monocytes have been observed in acute COVID‐19, whereas associations of monocyte count with long COVID were not sufficiently elucidated.MethodsA cohort study was conducted among COVID‐19 survivors discharged from hospital. The primary outcomes were core symptoms of long COVID, distance walked in 6 min, and lung function, and the secondary outcomes were health‐related quality
-
Patterns of Non‐influenza Respiratory Viruses Among Severe Acute Respiratory Infection Cases in Burkina Faso: A Surveillance Study Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-03-19 Moussa Lingani, Assana Cissé, Abdoul Kader Ilboudo, Issaka Yaméogo, Zekiba Tarnagada
BackgroundAlthough influenza viruses cause only one‐fifth of severe acute respiratory infections (SARI) in Burkina Faso, the other viral causes of SARI remain poorly investigated to inform clinical and preventive decision making.MethodsBetween 2016 and 2019, we prospectively enrolled inpatients meeting the World Health Organization (WHO) case definition of SARI in Burkina Faso. Results of viral etiologies
-
Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS‐CoV‐2 Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-03-19 Quentin Richier, Benjamin De Valence, Dorothée Chopin, Emmanuelle Gras, Laura I. Levi, Yasmine Abi Aad, Jérôme Pacanowski, Jean‐Luc Meynard, Léo Plaçais, Dorothée Fey, Priscille Couture, Guillaume Martin‐Blondel, Vincent Pestre, Juliette Woessner, Sophie Ancellin, Pierre Weyrich, Benjamin Carpentier, Salim Idri, Pierre Tiberghien, Laure Surgers, Thomas Hueso, Karine Lacombe
The emergence of SARS‐CoV‐2 Omicron variant has led to a complete reconfiguration of the therapeutic landscape, with all monoclonal antibodies having lost any neutralization activity. We report here a case series of 75 immunocompromised patients infected by the Omicron variant who benefited from COVID‐19 convalescent plasma (CCP). At Day 28, the overall survival was 76% (95% CI 67–86) with no significant
-
Risk of COVID‐19 Hospitalization and Protection Associated With mRNA Vaccination Among US Adults With Psychiatric Disorders Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-03-18 Matthew E. Levy, Duck‐Hye Yang, Margaret M. Dunne, Kathleen Miley, Stephanie A. Irving, Shaun J. Grannis, Zachary A. Weber, Eric P. Griggs, Talia L. Spark, Elizabeth Bassett, Peter J. Embi, Manjusha Gaglani, Karthik Natarajan, Nimish R. Valvi, Toan C. Ong, Allison L. Naleway, Edward Stenehjem, Nicola P. Klein, Ruth Link‐Gelles, Malini B. DeSilva, Anupam B. Kharbanda, Chandni Raiyani, Maura A. Beaton
BackgroundAlthough psychiatric disorders have been associated with reduced immune responses to other vaccines, it remains unknown whether they influence COVID‐19 vaccine effectiveness (VE). This study evaluated risk of COVID‐19 hospitalization and estimated mRNA VE stratified by psychiatric disorder status.MethodsIn a retrospective cohort analysis of the VISION Network in four US states, the rate of
-
Respiratory Syncytial Virus‐Associated Hospitalizations in Children: A 10‐Year Population‐Based Analysis in Finland, 2008–2018 Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-03-13 Erika Uusitupa, Matti Waris, Tytti Vuorinen, Terho Heikkinen
BackgroundThe risk of respiratory syncytial virus (RSV) hospitalization is highest during the first months of life, but few studies have assessed the population‐based rates of hospitalization in monthly age groups of infants.MethodsWe determined the average population‐based rates of hospitalization with virologically confirmed RSV infections in children ≤15 years of age admitted during the 10‐year
-
Real‐Life Comparison of Antivirals for SARS‐CoV‐2 Omicron Infection in Patients With Hematologic Malignancies Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-03-12 Tommaso Francesco Aiello, Olivier Peyrony, Mariana Chumbita, Patricia Monzó, Carlos Lopera, Pedro Puerta‐Alcalde, Laura Magnano, Francesc Fernández‐Avilés, Genoveva Cuesta, Montse Tuset, Josep Mensa, Jordi Esteve, Maria Angeles Marcos, Alex Soriano, Carolina Garcia‐Vidal
BackgroundWe aimed to describe a cohort of hematologic patients with COVID‐19 treated with antivirals early.MethodsNon‐interventional chart review study. Comparison of baseline characteristics and outcomes in high‐risk hematologic patients treated with remdesivir between December 2021 and April 2022 versus those treated with nirmatrelvir/ritonavir between May and August 2022.ResultsEighty‐three patients
-
Bidirectional Evolution of SARS‐CoV‐2 Virus in Immunocompromised Hosts Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-03-11 Charmaine W. Y. Chew, Barnaby E. Young, Paul A. Tambyah, Shawn Vasoo, Conrad E. Z. Chan
To the editor: SARS-CoV-2 has accumulated significant mutations to evade both vaccine- and infection-induced immunity. Some of the currently dominant Omicron subvariants are thought to have initially evolved in immunocompromised patients despite the lack of selection pressure from the host immune response or poor vaccine response [1]. Interestingly, some of these mutations such as K417N and F486S have
-
Rapid PCR Testing Reduces Antibiotic Prescribing in Children Presenting to Hospital With Lower Respiratory Tract Infections due to Influenza Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-02-29 Tony Walls, Emily Bowen, Ava Elsmore, Nathanael Lucas
Dear Sir/Madam We have previously demonstrated that in young children with lower respiratory tract infections (LRTI) admitted to hospital, identifying a virus on multiplex PCR testing of nasopharyngeal swabs (NPS) can lead to a reduction in antibiotic usage [1]. Rapid availability of viral PCR test results appears to provide additional antimicrobial stewardship benefits and can further reduce unnecessary
-
Issue Information Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-02-27
No abstract is available for this article.
-
Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-02-25 Angela M. C. Rose, Francisco Pozo, Iván Martínez-Baz, Clara Mazagatos, Nathalie Bossuyt, John Paul Cauchi, Goranka Petrović, Isabela I. Loghin, Roberta Vaikutyte, Silke Buda, Ausenda Machado, Róisín Duffy, Beatrix Oroszi, Jennifer Howard, Aitziber Echeverria, Cristina Andreu, Cyril Barbezange, Aušra Džiugytė, Diana Nonković, Corneliu-Petru Popescu, Fausta Majauskaite, Kristin Tolksdorf, Verónica Gomez
We conducted a multicentre hospital-based test-negative case–control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: −23–36);
-
Evolutionary analysis of seasonal influenza A viruses in Pakistan 2020–2023 Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-02-22 Nazish Badar, Aamer Ikram, Muhammad Salman, Sidra Saeed, Hamza Ahmed Mirza, Abdul Ahad, Massab Umair, Umer Farooq
Influenza A viruses cause global health concerns due to their high amino acid substitution rates. They are linked to yearly seasonal epidemics and occasional pandemics. This study focused on sequencing influenza A virus strains in Pakistan.
-
An algorithm for the characterization of influenza A viruses from various host species and environments Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-02-22 Laura A. Pulscher, Richard J. Webby, Gregory C. Gray
Due to the extensive host range of influenza A viruses, it is difficult to determine the best diagnostic algorithm to efficiently screen samples from a variety of host species for influenza A viruses. While there are some influenza diagnostic algorithms that are specific to host species, to our knowledge, no single algorithm exists for the characterization of influenza A viruses across multiple host
-
WHO's Investigations and Studies, Unity Studies: A global initiative creating equitable opportunities for enhanced surveillance, operational research, capacity building, and global knowledge sharing Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-02-12 Isabel Bergeri, Nicki L. Boddington, Hannah C. Lewis, Lorenzo Subissi, Sophie von Dobschuetz, Angel Rodriguez, Jorge Jara, Hala Abou El Naja, Amal Barakat, Arash Rashidian, Eman Abdelkreem Aly, Lubna Al Ariqi, Pushpa Wijesinghe, Francis Inbanathan, Phuong Nam Nguyen, Manilay Phengxay, Linh-Vi Le, Temuulen Enebish, Joseph Okeibunor, Belinda Herring, Elise Farley, Pernille Jorgensen, Aisling Marie Vaughan
The World Health Organization's Unity Studies global initiative provides a generic preparedness and readiness framework for conducting detailed investigations and epidemiological studies critical for the early and ongoing assessment of emerging respiratory pathogens of pandemic potential. During the COVID-19 pandemic, the initiative produced standardized investigation protocols and supported Member
-
Role of research Laboratories in pandemic and epidemic response in the Eastern Mediterranean Region: Experiences from COVID-19, avian influenza, and MERS-CoV Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-02-11 Mona Mahmoud, Rebecca Badra, Ahmed Kandeil, Rabeh El-Shesheny, Jad Abdallah, Mohamed A. Ali, Ghazi Kayali
We share the experience of research laboratories in the Eastern Mediterranean Region (EMR) that contributed to preparedness and response to highly pathogenic avian influenza (HPAI), Middle-East respiratory syndrome coronavirus (MERS-CoV), and coronavirus disease (COVID-19). Research groups in the region were pivotal in identifying, characterizing the pathogens and describing their evolution, distribution
-
High seroprevalence of severe acute respiratory syndrome coronavirus 2 among healthcare workers in Yaoundé, Cameroon after the first wave of Covid-19 pandemic and associated factors Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-02-11 Mathurin Cyrille Tejiokem, Hermine Abessolo Abessolo, Joseph Mendimi Nkodo, Mireille Ouethy, Georges Bouting Mayaka, Yannick Touha, Ulrich Armel Dikoume, Jules Brice Tchatchueng-Mbougua, Diane Choualeu Noumbissi, William Tsobeng Ndjeukam, Hervé Odilon Otabela Mbarga, Paul Alain Tagnouokam Ngoupo, Charlotte Moussi, Bonaventure Hollong Garoua, Richard Njouom, Vincent Richard
Healthcare workers (HWs) are at a high risk of exposure to emerging health threats. Following the first wave of the coronavirus disease 2019 pandemic in Cameroon, we explored the presence and persistence of naturally acquired antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the factors associated with seropositivity in HWs.
-
Functional decline at 1 year in hospitalized elderly pneumonia with SARS-CoV-2 Omicron variant: Comparison with the ancestral strain and Alpha variant Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-02-07 Naoyuki Miyashita, Yasushi Nakamori, Makoto Ogata, Naoki Fukuda, Akihisa Yamura, Tomoki Ito
In the SARS-CoV-2 Omicron period, the pattern of pneumonia changed from primarily viral pneumonia to pneumonia mixed with bacteria in the elderly. We investigated functional outcomes at 1 year after hospital discharge in patients with primary Omicron pneumonia and pneumonia mixed with bacteria, mainly aspiration pneumonia. Functional decline rates calculated using the Barthel Index at 1 year after
-
A phased strengthening of laboratory capacity in the Eastern Mediterranean Region during the COVID-19 pandemic Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-02-05 Luke W. Meredith, Mustafa Aboualy, Rachel Ochola, Mehmet Ozel, Abdinasir Abubakar, Amal Barakat
The Eastern Mediterranean Region (EMR) faces ongoing challenges in its public health system due to limited resources, logistical issues, and political disruptions. The COVID-19 pandemic accelerated the need for stronger laboratory capacities to handle the increased demand for testing. In a phased response, EMR countries utilized the National Influenza Centers to rapidly establish and scale molecular
-
The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-02-03 Desmond Curran, Sean Matthews, Eliazar Sabater Cabrera, Silvia Narejos Pérez, Lina Pérez Breva, Mika Rämet, Laura Helman, Dae Won Park, Tino F. Schwarz, Isabel Maria Galan Melendez, Axel Schaefer, Nathalie Roy, Brigitte Stephan, Daniel Molnar, Lusine Kostanyan, John H. Powers, Veronica Hulstrøm
-
Respiratory viral detection in the plasma and cerebrospinal fluid (CSF) of young febrile infants Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-02-01 Erin G. Nicholson, Vasanthi Avadhanula, Leila C. Sahni, Laura Ferlic-Stark, Lauren Maurer, Julie A. Boom, Pedro A. Piedra
Respiratory viral infections are common in febrile infants ≤90 days. However, the detection of viruses other than enterovirus in the blood and cerebrospinal fluid (CSF) of young infants is not well defined. We sought to quantify the occurrence of respiratory viruses in the blood and CSF of febrile infants ≤90 days.
-
Issue Information Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-01-30
No abstract is available for this article.
-
Internationally standardized respiratory viral load testing with limited resources: A derivative-of-care calibration strategy for SARS-CoV-2 Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-01-23 Lili Tao, Allison Chan, Alex Maris, Jonathan E. Schmitz
SARS-CoV-2 has demonstrated that, in targeted circumstances, viral quantification within respiratory specimens can valuably inform patient management, as well as research. Nevertheless, the pandemic has illustrated concomitant challenges for obtaining high-quality (and broadly comparable) respiratory viral loads. This includes a critical need for standardization and calibration, even though the necessary
-
Comparison of influenza viral load in nasopharyngeal and midturbinate swabs Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-01-21 Corrado Bernasconi, Laurie Katugampola, Steffen Wildum
Different specimen types are used for influenza diagnosis but comparative data for viral loads from different swab types are limited. We compared influenza viral loads (determined by quantitative reverse transcription polymerase chain reaction [RT-PCR]) in 93 paired midturbinate and nasopharyngeal swab aliquots from influenza infected patients enrolled in a phase 3 randomized-controlled study with
-
Quantified impacts of non-pharmaceutical interventions on influenza circulation during the COVID-19 pandemic in 13 African countries, 2020–2022 Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-01-18 Radhika Gharpure, Sonja J. Olsen, William W. Davis
Nonpharmaceutical interventions (NPIs) for SARS-CoV-2 disrupted circulation of influenza. We used data from 13 African countries and generalized linear models to identify associations between levels of NPIs, using the Oxford Stringency Index, and seasonal influenza activity, using parameters derived from 2020–2022 seasonal influenza surveillance. We found that for each step increase in school closings
-
Comparative analysis of mortality in patients admitted with an infection with influenza A/B virus, respiratory syncytial virus, rhinovirus, metapneumovirus or SARS-CoV-2 Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-01-18 Hanneke Boon, Arend-Jan Meinders, Erik Jan van Hannen, Matthijs Tersmette, Erik Schaftenaar
While influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are recognised as a cause of severe illness and mortality, clinical interest for respiratory syncytial virus (RSV), rhinovirus and human metapneumovirus (hMPV) infections is still limited.
-
Respiratory syncytial virus among hospitalized patients of severe acute respiratory infection in Bhutan: Cross-sectional study Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-01-17 Kunzang Dorji, Pema Yuden, Tara Devi Ghishing, Govinda Ghimeray, Chonticha Klungthong, Sonam Wangchuk, Aaron Farmer
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections worldwide, particularly in young children. In Bhutan, respiratory disease continues to be among the top 10 diseases of morbidity for several years. This study aimed to estimate the prevalence of RSV among hospitalized patients with severe acute respiratory infection (SARI) in Bhutan.
-
Effect of planned school breaks on student absenteeism due to influenza-like illness in school aged children—Oregon School District, Wisconsin September 2014–June 2019 Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-01-16 Cecilia He, Derek Norton, Jonathan L. Temte, Shari Barlow, Maureen Goss, Emily Temte, Cristalyne Bell, Guanhua Chen, Amra Uzicanin
School-aged children and school reopening dates have important roles in community influenza transmission. Although many studies evaluated the impact of reactive closures during seasonal and pandemic influenza outbreaks on medically attended influenza in surrounding communities, few assess the impact of planned breaks (i.e., school holidays) that coincide with influenza seasons, while accounting for
-
Relevance of comorbidities for main outcomes during different periods of the COVID-19 pandemic Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-01-16 José M. Quintana-Lopez, Lander Rodríguez, Janire Portuondo, Julia García, Maria Jose Legarreta, María Gascón, Nere Larrea, Irantzu Barrio
Throughout the evolution of the COVID-19 pandemic, the severity of the disease has varied. The aim of this study was to determine how patients' comorbidities affected and were related to, different outcomes during this time.
-
Influenza vaccine effectiveness in Europe: Results from the 2022–2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-01-10 Marine Maurel, Francisco Pozo, Gloria Pérez-Gimeno, Silke Buda, Noémie Sève, Beatrix Oroszi, Mariette Hooiveld, Verónica Gomez, Lisa Domegan, Iván Martínez-Baz, Maja Ilić, Anna Sara Carnahan, Maria Elena Mihai, Ana Martínez, Luise Goerlitz, Vincent Enouf, Judit Krisztina Horváth, Frederika Dijkstra, Ana Paula Rodrigues, Charlene Bennett, Camino Trobajo-Sanmartín, Ivan Mlinarić, Neus Latorre-Margalef
Influenza A(H3N2) viruses dominated early in the 2022–2023 influenza season in Europe, followed by higher circulation of influenza A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated the influenza vaccine effectiveness (VE) using a multicentre test-negative study.
-
Surveillance of seasonal influenza viruses during the COVID-19 pandemic in Tokyo, Japan, 2018–2023, a single-center study Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-01-05 Hidenori Takahashi, Hiroki Nagamatsu, Yuka Yamada, Naoya Toba, Mio Toyama-Kousaka, Shinichiro Ota, Miwa Morikawa, Masahiro Shinoda, Syunsuke Takano, Suzuko Fukasawa, Kaeyoung Park, Takahiko Yano, Masamichi Mineshita, Masaharu Shinkai
COVID-19 pandemic led to significant reductions in influenza detection worldwide, fueling debates on whether influenza truly ceased circulating in communities. The number of influenza cases decreased significantly in Japan, raising concerns about the potential risk of decreased immunity to influenza in the population. Our single-center study aimed to investigate influenza trends before and during the
-
In-field detection and characterization of B/Victoria lineage deletion variant viruses causing early influenza activity and an outbreak in Louisiana, 2019 Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-01-05 Bo Shu, Malania M. Wilson, Matthew W. Keller, Ha Tran, Theresa Sokol, Grace Lee, Benjamin L. Rambo-Martin, Marie K. Kirby, Norman Hassell, Danielle Haydel, Julie Hand, David E. Wentworth, John R. Barnes
In 2019, the Louisiana Department of Health reported an early influenza B/Victoria (B/VIC) virus outbreak.
-
Comparison of the Oxford COVID-19 Government Response Tracker and the ECDC-JRC Response Measures Database for nonpharmaceutical interventions Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-01-02 Susanne Heemskerk, Peter Spreeuwenberg, Harish Nair, John Paget
During the COVID-19 pandemic, governments implemented different public health measures and interventions to control COVID-19. These wide-ranging public health interventions, also known as non-pharmaceutical interventions (NPIs), have been documented in Europe in two different publicly available databases. In the context of an EU-funded research project aimed at Preparing for Respiratory Syncytial Virus
-
Issue Information Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2024-01-01
No abstract is available for this article.
-
Seroprevalence of SARS-CoV-2 infection in the general population of Nepal during the first and second generalized waves of the COVID-19 pandemic—2020–2021 Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2023-12-27 Krishna Prasad Paudel, Reuben Samuel, Runa Jha, Basu Dev Pandey, Chathura Edirisuriya, Nebin Lal Shrestha, Pradip Gyawali, Amrit Pokhrel, Lilee Shrestha, Ram Kumar Mahato, Shaikh Shah Hossain, Govindakarnavar Arunkumar, Anindya Sekhar Bose, Meghnath Dhimal, Dipendra Gautam, Subash Neupane, Nishant Thakur, Saugat Shrestha, Nirajan Bhusal, Priya Jha, Binod Prasad Gupta, Rajan Bikram Rayamajhi, Koshal
Few seroprevalence studies have been conducted on coronavirus disease (COVID-19) in Nepal. Here, we aimed to estimate seroprevalence and assess risk factors for infection in the general population of Nepal by conducting two rounds of sampling. The first round was in October 2020, at the peak of the first generalized wave of COVID-19, and the second round in July–August 2021, following the peak of the
-
Avian influenza A(H5) virus circulation in live bird markets in Vietnam, 2017–2022 Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2023-12-27 Diep T. Nguyen, Kelsey M. Sumner, Thoa T. M. Nguyen, Minh Q. Phan, Tien M. Hoang, Chuong D. Vo, Tho D. Nguyen, Phuong T. Nguyen, Genyan Yang, Yunho Jang, Joyce Jones, Sonja J. Olsen, Philip L. Gould, Long V. Nguyen, Charles Todd Davis
Highly pathogenic avian influenza A(H5) human infections are a global concern, with many A(H5) human cases detected in Vietnam, including a case in October 2022. Using avian influenza virus surveillance from March 2017–September 2022, we described the percent of pooled samples that were positive for avian influenza A, A(H5), A(H5N1), A(H5N6), and A(H5N8) viruses in live bird markets (LBMs) in Vietnam
-
Comparison of the clinical features and outcomes of severe seasonal influenza and COVID-19 patients in Tunisia between 2021 and 2022 Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2023-12-20 Jalila Ben Khelil, Rihab Yazidi, Nacef Ben Mrad, Fatma Jarraya, Emna Rachdi, Samia Ayed, Amira Jamoussi, Afif Ben Salah, Mohamed Besbes
We compared patients diagnosed at a SARI (severe acute respiratory infections) surveillance site with COVID-19 and those with seasonal influenza to investigate the clinical differences, common features, and outcomes.
-
Sex differences in COVID-19 symptom severity and trajectories among ambulatory adults Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2023-12-19 Samuel P. Massion, Amanda C. Howa, Yuwei Zhu, Ahra Kim, Natasha Halasa, James Chappell, Trey McGonigle, Alexandra M. Mellis, Jessica E. Deyoe, Carrie Reed, Melissa A. Rolfes, H. Keipp Talbot, Carlos G. Grijalva
The ongoing COVID-19 pandemic has led to hundreds of millions of infections worldwide. Although differences in COVID-19 hospitalization rates between males and females have been described, many infections in the general population have been mild, and the severity of symptoms during the course of COVID-19 in non-hospitalized males and females is not well understood.
-
Performance of established disease severity scores in predicting severe outcomes among adults hospitalized with influenza—FluSurv-NET, 2017–2018 Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2023-12-17 Joshua D. Doyle, Shikha Garg, Alissa C. O'Halloran, Lauren Grant, Evan J. Anderson, Kyle P. Openo, Nisha B. Alden, Rachel Herlihy, James Meek, Kimberly Yousey-Hindes, Maya L. Monroe, Sue Kim, Ruth Lynfield, Melissa McMahon, Alison Muse, Nancy Spina, Lourdes Irizarry, Salina Torres, Nancy M. Bennett, Maria A. Gaitan, Mary Hill, Charisse N. Cummings, Carrie Reed, William Schaffner, H. Keipp Talbot, Wesley
Influenza is a substantial cause of annual morbidity and mortality; however, correctly identifying those patients at increased risk for severe disease is often challenging. Several severity indices have been developed; however, these scores have not been validated for use in patients with influenza. We evaluated the discrimination of three clinical disease severity scores in predicting severe influenza-associated
-
Impact of antiviral therapy on short- and long-term outcomes of patients with chronic obstructive pulmonary disease after influenza infection Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2023-12-13 Christopher Wallick, Tu My To, Stephan Korom, Henry Masters, Ning Wu, Dalia Moawad, Nicola A. Hanania
Respiratory complications often accompany influenza in patients with chronic obstructive pulmonary disease (COPD). In this retrospective study, we quantified the impact of antiviral therapy on exacerbations, healthcare resource utilization (HRU), and costs in patients with COPD across 5 influenza seasons.
-
Time trend of respiratory viruses before and during the COVID-19 pandemic in severe acute respiratory virus infection in the Sultanate of Oman between 2017 and 2022 Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2023-12-13 Hanan Al Kindi, Luke William Meredith, Amina Al-Jardani, Fathima Sajina, Intisar Al Shukri, Rehan al Haj, Fatma Alyaquobi, Adil Al Wahaibi, Amal Al Maani
Severe acute respiratory illness (SARI) is a potentially lethal condition, necessitating thorough medical care. COVID-19 underscored the SARI threat, but other high-risk pathogens require monitoring alongside SARS-CoV-2. Oman instituted a comprehensive testing system to gauge the prevalence of these pathogens between 2017 and 2021, aiding resource allocation and public health responses to potential
-
Role of Laboratory in Emerging Infectious Disease Control in Iran, Pasteur Institute of Iran, and national laboratory network Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2023-12-10 Ali Maleki, Ehsan Mostafavi, Mehdi Fazlalipour, Mostafa Salehi-Vaziri
Strengthening surveillance systems is a key aspect of outbreak response and was particularly important during the COVID-19 pandemic. Respiratory pathogens spread rapidly, and laboratory capacity is key to monitoring the spread. Prior to the pandemic, Iran had established a rapid response team and laboratory network to provide identification, monitoring, and detection of emerging infectious diseases
-
Modeling the impact of COVID-19 nonpharmaceutical interventions on respiratory syncytial virus transmission in South Africa Influenza Other Respir. Viruses (IF 4.4) Pub Date : 2023-12-10 Samantha J. Bents, Cécile Viboud, Bryan T. Grenfell, Alexandra B. Hogan, Stefano Tempia, Anne von Gottberg, Jocelyn Moyes, Sibongile Walaza, Chelsea Hansen, Cheryl Cohen, Rachel E. Baker
The South African government employed various nonpharmaceutical interventions (NPIs) to reduce the spread of SARS-CoV-2. Surveillance data from South Africa indicates reduced circulation of respiratory syncytial virus (RSV) throughout the 2020–2021 seasons. Here, we use a mechanistic transmission model to project the rebound of RSV in the two subsequent seasons.